July 28, 2025

The Food and Drug Administration’s Office of Inspections and Investigations (OII) Office of Import Operations (OIO) is implementing important changes to our import entry review process that will impact the way you engage with FDA importย operations.ย โ€ฏย 

ย 

Effective,ย August 4, 2025, OIOย will implement theย Nationalized Entry Review (NER)ย program to address the increasing volume of imported FDA-regulated commodities driven by e-commerce growth, expanded trade volume, and supply chain complexities.โ€ฏโ€ฏย 

ย 

What’s Changingโ€ฏโ€ฏย 

The NER program revolutionizes FDA’s import operations by implementing a standardized, efficient, and technology-driven approach to entry reviews across all ports of entry. We are transitioning from our current geographic location model to a national-based review system that will:โ€ฏโ€ฏย 

  • Conduct entry admissibility reviews on a national basis versus the current port-by-port entry review approachย ย 
  • Utilize staff across multiple time zones for expanded coverageย ย 
  • Explore automation opportunities to streamline processesย ย 
  • Optimize resource allocation to focus on higher-risk productsโ€ฏโ€ฏย 

ย 

What is NOT Changingโ€ฏโ€ฏย 

  • โ€ฏReview Processes and Standards: Our established entry review procedures, quality standards, and regulatory requirements remain unchangedโ€ฏโ€ฏย 
  • โ€ฏReview Criteria: The methods and standards we use to evaluate entries will continue as beforeโ€ฏโ€ฏย 

ย 

  • โ€ฏPublic Health Protection: Our commitment to identifying and addressing risks in imported products remains our top priorityโ€ฏโ€ฏย 
  • All other processes and requirements remain the same.ย ย As this is an internal operational enhancement, the NER program modernization requires only one change for industry: Modifying how you contact FDA regarding status of shipments under entry review that have not already gone to the Field for assigned work using theย NERInquiry@fda.hhs.govย email address.ย ย Contact Information (Effective August 4, 2025)ย 

ย โ€ฏโ€ฏย 

โ€ฏCRITICAL:โ€ฏ New communication protocols have been established effective August 4, 2025,โ€ฏโ€ฏ

Entry Status Inquiriesย 

  1. Initial review statusย (pending review, documents requested, etc.):ย NERInquiry@fda.hhs.govย 
  2. Field review statusย (pending exam/sampling, detained, refused, etc.): Contact the appropriate division atย FDA Import Offices and Ports of Entryย 

ย ย 

General Import Questionsย 

  1. General import operation questions:ย imports@fda.hhs.govย or 301-796-0356ย ย 
  2. Prior notice for food products:ย prior.notice@fda.hhs.govย or 866-521-2297ย 
  3. ITACS issues:ย ITACSSupport@fda.hhs.govย 
  4. NER program questions:ย NERInquiry@fda.hhs.govย 
  5. For all other inquiries, seeย Contact the FDA Programย 

ย ย 

Email Guidelines for NER Inquiriesย 

When contactingย NERInquiry@fda.hhs.gov:ย 

  • Use this mailbox only for checking status of entries under initial review or providing entry documents.ย 
  • Email only one FDA mailbox at a time (sending out to multiple boxes may delay your response)ย ย ย 
  • Use proper subject line formatting:ย 

Subject Line Format Exampleย 

  1. Entry number (one entry number per email)ย 
  2. Spaceย 
  3. Commodity type:ย ย 
  4. Animal Foods, Animal Drugs, Animal Devices, Biologics, Cosmetics, Dietary Supplements, Food Related Products, Human Drugs, Human Foods, Infant Formula, Medical Devices, Medicated Feed, Rad Health Products, Tobacco, Multipleย 
  5. Spaceย 
  6. Port codeย 

Examples of properly formatted subject lines:ย 

  • 000-1234567-8 Food 2704ย 
  • 987-7654321-0 Multiple 4601ย 

ย ย 

Rememberย 

  • CheckITACSfor real-time entry status before contacting the NER Team.ย 
  • Always provide accurate information.ย 
  • Use ITACS whenever possible for faster processing.ย 
Contact us
Thank you for your interest in Garg Law PLLC.
Our commitment to understanding your regulatory questions and business goals, and helping you achieve results starts here.
If you are looking for representation on a new matter, please fill out the form below to request a free consultation. The form enables us to conduct a preliminary check for potential conflicts of interest and to determine if we can proceed with the free consultation.
Garg Law Global Icon

News & Insights

Get the latest news on FDA regulatory delivered straight to your inbox.